• Explore /
  • Poster
  • / Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study.

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study.

Abstract Poster

Authors

null

Andrew X. Zhu

Massachusetts General Hospital Cancer Center, Boston, MA

Andrew X. Zhu , Baek-Yeol Ryoo , Chia-Jui Yen , Masatoshi Kudo , Ronnie Tung-Ping Poon , Davide Pastorelli , Jean-Frédéric Blanc , Hyun Cheol Chung , Ari David Baron , Tulio Eduardo Flesch Pfiffer , Takuji Okusaka , Katerina Kubackova , Jorg Trojan , Javier Sastre , Ian Chau , Shao-Chun Chang , Paolo Abada , Ling Yang , Yanzhi Hsu , Joon Oh Park

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01140347

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 232)

DOI

10.1200/jco.2015.33.3_suppl.232

Abstract #

232

Poster Bd #

A3

Abstract Disclosures

Similar Posters

First Author: Maria Reig

First Author: Shukui Qin

First Author: Josep M. Llovet

First Author: Masatoshi Kudo